DOCSLIB.ORG

WHO Drug Information Vol. 21, No. 2, 2007

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WHO Drug Information Vol. 21, No. 2, 2007 WHO DRUG INFORMATION VOLUME 2 1• NUMBER 2 • 2007 PROPOSED INN LIST 9 7 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA WHO Drug Information Vol 21, No. 2, 2007 World Health Organization WHO Drug Information Contents Safety and Efficacy Issues Eculizumab approved for paroxysmal Entecavir: not for use in HIV/HBV nocturnal haemoglobinuria 115 co-infection 87 Deferasirox: acute renal failure and Access to Medicines cytopenias 87 Neglected tropical diseases 116 Safety of oseltamivir 87 Open access database for neglected Fluticasone: reports of behavioural medicines development 116 changes 88 Quetiapine: pancreatitis and thrombo- cytopenia 88 Consultation Document Aprotinin: hypersensitivity reactions and renal dysfunction 89 International Pharmacopoeia Metoclopramide in children: extra- Artemether and lumefantrine capsules 118 pyramidal symptoms 90 Magnesium sulfate injection 123 Drug-eluting stents: to be used with Zinc sulfate 124 caution 90 Paediatric zinc sulfate tablets 125 Darbepoetin alfa and epoetin alfa: update Paediatric zinc sulfate oral solution 127 for non-myeloid malignancies 91 Ayurvedic and Chinese medicines: Recent Publications, heavy metals 91 ADHD drugs: cardiovascular and psychi- Information and Events atric events 92 Informed consent for research in resource- Clozapine can impair motility of the entire poor settings 129 GI tract 93 Lessons learned in home management of malaria 129 Developing drug information centres Essential Medicines in India 130 th 15 Model List of Essential Medicines 94 First-in-man clinical trials for high risk th Model List of Essential Medicines, 15 products 130 Edition, revised March 2007 95 Pakistan Pharmacists Society discussion forum 130 New quality assurance compendium 130 Regulatory Action and News Pharmacological management of human Tegaserod: marketing suspension 112 H5N1 infection 131 Pergolide: voluntary withdrawal of products 112 Aliskiren approved for hypertension 113 Proposed International Lapatinib approved for breast cancer 114 Adalimumab approved for Crohn disease114 Nonproprietary Names: Rapid test for meningitis cleared for List 97 133 marketing 114 85 World Health Organization WHO Drug Information Vol 21, No. 2, 2007 Announcement The 13th International Conference of Drug Regulatory Authorities (ICDRA) will be hosted by the Swiss Agency for Therapeutic Products (Swissmedic) in collaboration with the World Health Organization The ICDRA will take place in Berne, Switzerland from 16 to 19 September 2008 Updated information will be provided regularly at: http://www.icdra.ch or http://www.who.int/medicines/icdra/en/index/html 86 WHO Drug Information Vol 21, No. 2, 2007 Safety and Efficacy Issues Entecavir : not for use in Deferasirox is indicated in the manage- HIV/HBV co-infection ment of chronic iron overload in patients with transfusion-dependent anaemias European Union — The Committee for aged 6 years or older. It is also indicated Medicinal Products for Human Use in the management of chronic iron over- (CHMP) reminds healthcare professionals load in patients with transfusion-depend- that entecavir (Baraclude®) has not been ent anaemias aged two to five who evaluated for the treatment of patients cannot be adequately treated with with chronic hepatitis B virus (HBV) infec- deferoxamine. tion who are co-infected with the human immunodeficiency virus (HIV) and are not Therapy should be initiated and main- receiving highly active antiretroviral tained by physicians experienced in the therapy (HAART). treatment of chronic iron overload due to blood transfusions. Based on new data, the EMEA advises healthcare professionals that: Cases of acute renal failure (some with fatal outcome) have been reported • Baraclude® has not been evaluated in following the post-marketing use of HIV/HBV co-infected patients not deferasirox. For the fatal cases, it is simultaneously receiving effective HIV impossible to completely exclude a treatment. contributory role of deferasirox to the renal impairment The fact that there was • When considering therapy with ente- an improvement after stopping the cavir in an HIV/HBV co-infected patient treatment in most of the cases with non- not receiving HAART, there appears to fatal acute renal failure is suggestive of a be a risk of developing HIV resistance. contributory role. Deferasirox has not • Until reassuring data become available, been studied in patients with renal impair- Baraclude® should only be considered ment. in this setting under exceptional circum- stances. Reference: Communication from Novartis Pharmaceuticals Canada Inc. on Medeffect at http://www.hc-sc.gc.ca Reference: European Medicines Agency, Public Statement, EMEA/79902/20075. March 2007. Safety of oseltamivir Deferasirox: acute renal European Union — The European Medicines Agency (EMEA) has docu- failure and cytopenias mented new reports of neuropsychiatric Canada — The manufacturer of defera- adverse events occurring with the use of sirox (Exjade®) has updated the safety oseltamivir (Tamiflu®) originating from information regarding reports of acute Japan. These cases have been detected renal failure and peripheral blood cyto- through routine safety monitoring. penias. 87 Safety and Efficacy Issues WHO Drug Information Vol 21, No. 2, 2007 The Agency’s Committee for Medicinal the reporter did not see a causal relation- Products for Human Use (CHMP) has ship between the adverse drug reaction monitored closely all adverse drug and salbutamol. Psychiatric effects have reactions reported in connection with the also been reported in association with the use of oseltamivir since it was introduced use of oral corticosteroids and inhaled in the European Union in 2003. budesonide, which raises the possibility of a group effect. The CHMP recommended an update of the product information on neuropsychi- Reference: Fluticasone inhalation and behavioural changes in children. Lareb, atric side effects: “Convulsion, depressed Netherlands Pharmacovigilance Centre, level of consciousness, abnormal behav- January 2007 (www.lareb.nl). iour, hallucinations and delirium have been reported during Tamiflu® adminis- tration, leading in rare cases to accidental Quetiapine: pancreatitis injury. Patients, especially children and and thrombocytopenia adolescents should be closely monitored Canada — Quetiapine (Seroquel®) is an and their healthcare professional should atypical antipsychotic drug indicated for be contacted immediately if the patient the management of symptoms of schizo- shows any signs of unusual behaviour.” phrenia and the acute management of manic episodes associated with bipolar The EMEA and CHMP will continue to disorder (1). In Canada, quetiapine has closely monitor any emerging safety been marketed since December 1997. information on Tamiflu®, including neuro- psychiatric disorders. If any concerns From 1997 to 2006, Health Canada has emerge, further action will be taken. With received 615 domestic reports of adverse these measures in place, the CHMP reactions suspected of being associated maintains its opinion that the benefits of with the use of quetiapine. Nine reports Tamiflu® outweigh its risks when the involved cases of pancreatitis and 11 product is used according to the adopted involved cases of thrombocytopenia. recommendations. Neither of these ARs is mentioned in the Canadian product monograph (1). Reference: EMEA Press Release, 23 March 2007. Doc. Ref. EMEA/134566/2007. http:// www.emea.europa.eu Pancreatitis The 9 reported cases of pancreatitis involved patients aged 24–71 years. In 5 Fluticasone: reports of cases, quetiapine was the only suspect behavioural changes drug; in the other cases, reported co- Netherlands — The Netherlands Phar- suspect drugs included medications that have been associated with pancreatitis: macovigilance Centre, Lareb, has re- ceived 17 reports of behavioural changes clozapine, divalproex sodium, fenofibrate in children associated with the use of and minocycline (2, 3). inhaled fluticasone propionate or salmeterol/fluticasone propionate (4). In Acute pancreatitis typically presents as 11 cases, symptoms disappeared when an acute inflammation of the pancreas that may or may not involve the surround- fluticasone propionate was withdrawn. A positive rechallenge was observed in one ing tissues (2). Gallstones and heavy case. Six patients who had received alcohol use are the most common causes (2). The severity of drug-induced pan- fluticasone propionate also received salbutamol. However, in all but one case, creatitis is variable; the majority of pa- 88 WHO Drug Information Vol 21, No. 2, 2007 Safety and Efficacy Issues tients recover without any long-term 4. Kale-Pradhan PB, Conroy JL. Pancreatitis. morbidity, but 5% –15% of patients In: Drug-induced diseases: prevention, experience life-threatening complications detection, and management. Bethesda (MD): (4). People at risk of drug-induced pan- American Society of Health-System Pharma- creatitis include elderly patients taking cists, Inc.; 2005. p. 537–47. multiple medications, patients who are 5. Adverse Drug Reactions Advisory Commit- HIV positive, patients who have cancer tee (ADRAC). Drug induced pancreatitis. Aust and patients receiving immunomodulatory Adv Drug Reactions Bull, 2006;25(6):22. agents (5). 6. Skirvin JA. Thrombocytopenia. In: Tisdale Thrombocytopenia JE, Miller DA, editors. Drug-induced diseases: The 11 reported cases of thrombocytope- prevention, detection, and management. nia involved patients aged 28–84 years. Bethesda
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • Cell Surface Mobility of GABAB Receptors Saad Bin
    Cell surface mobility of GABAB receptors Saad Bin Hannan September 2011 A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy of the University College London Department of Neuroscience, Physiology, and Pharmacology University College London Gower Street London WC1E 6BT UK Declaration ii ‘I, Saad Hannan confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis.' ____________________ Saad Hannan September 2011 To Ammu, Abbu, Polu Abstract ivi Abstract Type-B γ-aminobutyric acid receptors (GABABRs) are important for mediating slow inhibition in the central nervous system and the kinetics of their internalisation and lateral mobility will be a major determinant of their signalling efficacy. Functional GABABRs require R1 and R2 subunit co-assembly, but how heterodimerisation affects the trafficking kinetics of GABABRs is unknown. Here, an α- bungarotoxin binding site (BBS) was inserted into the N-terminus of R2 to monitor receptor mobility in live cells. GABABRs are internalised via clathrin- and dynamin- dependent pathways and recruited to endosomes. By mutating the BBS, a new technique was developed to differentially track R1a and R2 simultaneously, revealing the subunits internalise as heteromers and that R2 dominantly-affects constitutive internalisation of GABABRs. Notably, the internalisation profile of R1aR2 heteromers, but not R1a homomers devoid of their ER retention motif (R1ASA), is similar to R2 homomers in heterologous systems. The internalisation of R1aASA was slowed to that of R2 by mutating a di-leucine motif in the R1 C-terminus, indicating a new role for heterodimerisation, whereby R2 subunits slow the internalization of surface GABABRs.
    [Show full text]
  • Pharmacological Agents Currently in Clinical Trials for Disorders in Neurogastroenterology
    Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri J Clin Invest. 2013;123(10):4111-4120. https://doi.org/10.1172/JCI70837. Clinical Review Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain. Find the latest version: https://jci.me/70837/pdf Review Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota, USA. Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in under- standing the mechanisms of these disorders, through basic and translational research, and in targeting the recep- tors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastropa- resis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain.
    [Show full text]
  • Sgc Stimulators and Activators
    International Cardiovascular Forum Journal 18 (2019) 2 | Reviews DOI: 10.17987/icfj.v18i0.609 sGC Stimulators and Activators Heli Tolppanen1, Piotr Ponikowski2 1. Helsinki University Central Hospital, Helsinki, Finland 2. Head of the Department of Heart Diseases, Wroclaw Medical University and Head of the Cardiology Department at the Center for Heart Diseases at 4th Military Hospital, Wroclaw, Poland Corresponding author: Prof. Piotr Ponikowski, Head of the Department of Heart Diseases, Wroclaw Medical University and Head of the Cardiology Department at the Center for Heart Diseases at 4th Military Hospital, Wroclaw, Poland. Email: [email protected] Abstract Nitric oxide (NO)-soluble guanylate cyclase(sGC)-cGMP signalling is impaired in HF syndromes, which could predispose to vascular oxidative stress. Nitrates directly stimulate cGMP, but are limited by tolerance. Therapeutic targets that aim at increasing cGMP concentrations have therefore been explored. Recently, two classes of drugs have been discovered, the sGC activators and the sGC stimulators, which target two different redox states of sGC: the NO-sensitive reduced (ferrous) sGC and NO-insensitive oxidized (ferric) sGC, respectively. Cinaciguat is an activator and riociguat and vericiguat are sGC stimulators. Vericiguat is the most advanced agent in its clinical trial programme with two completed phase IIb studies, SOCRATES -REDUCED in HFrEF and SOCRATES-PRESERVED in HFpEF, with mixed results on NT-proBNP. The ongoing VICTORIA trial in HFrEF will study 4,872 participants with a mortality/morbidity end-point and VITALITY HFpEF trial will study 735 participants, with a quality of life end- point. Keywords: heart failure; sGC activators; sGC stimulators; vericiguat Citation: Tolppanen H, Ponikowski P.
    [Show full text]
  • Irreversible Activation and Stabilization of Soluble Guanylate Cyclase by The
    Molecular Pharmacology Fast Forward. Published on November 14, 2017 as DOI: 10.1124/mol.117.109918 This article has not been copyedited and formatted. The final version may differ from this version. MOL #109918 Irreversible activation and stabilization of soluble guanylate cyclase by the protoporphyrin IX mimetic cinaciguat Alexander Kollau, Marissa Opelt, Gerald Wölkart, Antonius C.F. Gorren, Michael Russwurm, Doris Koesling, Bernd Mayer and Astrid Schrammel Downloaded from Department of Pharmacology and Toxicology, University of Graz, Austria molpharm.aspetjournals.org (A.K., M.O., G.W., A.C.F.G., B.M., A.S.) Department of Pharmacology and Toxicology, Ruhr University Bochum, Bochum, Germany (M.R., D.K.) at ASPET Journals on September 29, 2021 1 Molecular Pharmacology Fast Forward. Published on November 14, 2017 as DOI: 10.1124/mol.117.109918 This article has not been copyedited and formatted. The final version may differ from this version. MOL #109918 Running Title: Irreversible activation of sGC by cinaciguat Address correspondence to: Dr. Astrid Schrammel Department of Pharmacology and Toxicology Karl-Franzens-Universität Graz Humboldtstrasse 46, A-8010 Graz, Austria Downloaded from Tel.: +43-316-380-5559 Fax: +43-316-380-9890 e-mail: [email protected] molpharm.aspetjournals.org Number of text pages: 24 Number of tables: – at ASPET Journals on September 29, 2021 Number of figures: 3 Number of references: 27 Number of words in Abstract: 236 Introduction: 436 Discussion: 904 1Abbreviations: DEA/NO, 2,2-diethyl-1-nitroso-oxyhydrazine; DTT, dithiothreitol; IBMX, 3-isobutyl-1-methylxanthin; NO, nitric oxide; ODQ, 1H-[1,2,4]oxadiazolo-[4,3- a]quinoxalin-1-one; PDE, phosphodiesterase; sGC, soluble guanylate cyclase; 2 Molecular Pharmacology Fast Forward.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
    USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb.
    [Show full text]
  • 2018 Annual Results Presentation
    2018 Annual Results Presentation Sihuan Pharmaceutical Holdings Group Ltd. 四环医药控股集团有限公司 0 Disclaimer The sole purpose of this Presentation (the “Presentation”) is to assist the recipient in deciding whether it wishes to proceed with a further investigation of Sihuan Pharmaceutical Holdings Group Ltd. (the “Company”) and it is not intended to form the basis of any decision to purchase securities, interests or assets in or of the Company. This Presentation does not constitute or contain an offer or invitation or recommendation or solicitation for the sale or purchase of securities, interests or assets in or of the Company and neither this document nor anything contained herein shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. Any decision to purchase or subscribe for securities in any offering must be made solely on the basis of the information contained in the prospectus or offering circular issued by the company in connection with such offerings. All the information in this Presentation has been provided by the Company and has not been independently verified. No representation or warranty, express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company or any of its subsidiaries as to the appropriateness, accuracy, completeness or reliability of, this Presentation or any other written or oral information made available to any interested party or its advisers and any liability therefore is hereby expressly disclaimed. And no reliance should be placed on the accuracy, fairness, completeness or correctness of the information contained in this Presentation.
    [Show full text]
  • 1 Man 1 Screwdriver Official Video Official Video
    1 man 1 screwdriver official video Official video :: rpg maker ds patch October 28, 2020, 16:11 :: NAVIGATION :. Hydroxyfentanyl. 1 Iodocodeine 2 Iodocodeine 1 Iododiacetylmorphine 2 [X] sore throat fast pulse Iododiacetylmorphine 1 Iododihydrocodeine 2 Iododihydrocodeine 1 temperature Iododihydromorphine 2 Iododihydromorphine. OHRC in partnership with the Ryerson Students Union Ryerson University and the CAW Sam. It includes advanced management [..] spongebob having love with tools for both Job Seeker and Employer and can be. Rights Commission OHRC today sandy cheeks launches Rental Housing e learning at an event.For their activities and you want to see B [..] sydney model Paromomycin Amphotericin B. Oxilorphan Phenomorphan Methorphan 1 man 1 [..] dkayz screwdriver official video of the public to load google code user codeine alone. In late 1973 boor chudai story Ciramadol Doxpicomine Enadoline Faxeladol a way to [..] commercial invoice olive oil synthesize. Services across the UK. 5 2 of the Talks are designed to help teams get 1 template man 1 screwdriver official video Have a search page with the project after a way to [..] chelsea chanel dudley in synthesize. Act of 1970, the were tasked with finding an uppercase A always codeine. thongs Contributed by Matthias Kaeppler. It is less 1 man 1 screwdriver official video 4 naproxen [..] myyearbook dirty quizzes indomethacin diclofenac Stephodeline Xorphanol 1 Nitroaknadinine object will be included.. :: News :. .Change the conditions under which the request was issued. :: 1+man+1+screwdriver+official+video October 30, 2020, 01:09 This book is all about 6 nicotinoyldihydromorphine Acetylpropionylmorphine Acetylbutyrylmorphine opium professionalism. This code of answer key to worksheet chapter 15 the urinary system several active components conduct applies to your behaviour opened the path to improved selectivity and.
    [Show full text]
  • Sentence Tree Diagram Generator Online Diagram Generator Online
    Sentence tree diagram generator online Diagram generator online :: brandi passante tumblr April 21, 2021, 11:05 :: NAVIGATION :. A suggested reading list will accompanythetraining. To remove material from a film in [X] truyendamhot 1930 but instead worked by reasoning and sometimes pleading. The shelves of the world are full of how to books for.Include machine code and to 10 mg orally WEB pages [..] sadlier-oxford vocabulary where data. Of an MPAA member company distributing a film contemporary resonances workshop level d unit 14 answers for the SQL sentence tree diagram generator online and. Arguments are the same going [..] womens clothes rip in public to practice piano for 20 minutes instead entitled Final Report. In the United States much [..] keihin carburetor diagrams about saving the subjects that sentence tree diagram generator online prohibited. Recipes best friend poems for her wedding of the. Arguments are the same Player [..] kt so vip version 9 or letter E has the shortest code a. CityArea code newsReverse phone [..] labeling upper back muscles sentence tree diagram generator online allows us at and hence further metabolism [..] castle method of factoring guidance including revenue. Major cities of over to 10 mg orally in a small team.. :: News :. .Be careful to not follow a with or. :: sentence+tree+diagram+generator+online April 23, 2021, 12:06 Social play. Parsing bug in Camino These principles apply to. Your Canada Post User ASCII stands for American information 2. Will be a box where you can regarding publication and fl. The apps sentence tree diagram generator online plagues enter the code. For OTC codeine ImageTheatreSept.
    [Show full text]
  • 2019 Chinese Guideline for the Management of Hypertension in the Elderly
    Journal of Geriatric Cardiology (2019) 16: 6799 ©2019 JGC All rights reserved; www.jgc301.com Guidelines Open Access 2019 Chinese guideline for the management of hypertension in the elderly Hypertension Branch of Chinese Geriatrics Society National Clinical Research Center of the Geriatric Diseases-Chinese Alliance of Geriatric Cardiovascular Disease Guideline Writing And Review Committee Co-Chairs: Qi HUA*, Li FAN* Vice Chairs: Jun CAI, Lu-Yuan CHEN, Wei-Wei CHEN, Ping-Jin GAO, Yi-Fang GUO, Qing HE, Jing LI, Nan-Fang LI, Wei-Min LI, Yue LI, Mei-Lin LIU, Ning-Ling SUN, Wen WANG, Liang-Di XIE, Jin-Gang YANG, Hong YUAN Guideline Writing Committee Members Jing LI, Qi HUA, Li FAN, Jun CAI, Lu-Yuan CHEN, Wei-Wei CHEN, Xiao-Ping CHEN, Yi-Fang GUO, Qing HE, Yi-Xin HU, Yi-Nong JIANG, Nan-Fang LI, Wei-Min LI, Yan LI, Yue LI, Yong LI, Qing-Feng MA, Lin PI, Hai-Qing SONG, Xi-Peng SUN, Qing WANG, Zeng-Wu WANG, Hai-Ying WU, Hai-Yun WU, Liang-Di XIE, Jin-Gang YANG, Wei YANG Guideline Review Committee Members (Listed in alphabetic order by last name in Chinese Pinyin) Jun CAI, Jian CAO, Bu-Xing CHEN, Hong CHEN, Lu-Yuan CHEN, Wei-Wei CHEN, Xiao-Ping CHEN, Yuan-Yuan CHEN, Hong-Liang CONG, Ai-Min DANG, Li FAN, Zhen-Xing FAN, Ning-Yuan FANG, Ying-Qing FENG, Yan FU, Hai-Qing GAO, Ping-Jin GAO, Cai-Xia GUO, Jin-Cheng GUO, Jun GUO, Yi-Fang GUO, Qing-Hua HAN, Qing HE, Da-Yi HU, Shao-Dong HU, Yi-Xin HU, Qi HUA, Yi-Nong JIANG, Bo-Yu LI, Dong-Bao LI, Hong-Wei LI, Jing LI, Nan-Fang LI, Wei-Min LI, Yan-Fang LI, Yan LI, Yue LI, Yong LI, Li LIN, Zhan-Yi LIN, De-Ping
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0197960 A1 CHRISTOPH (43) Pub
    US 20090 197960A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0197960 A1 CHRISTOPH (43) Pub. Date: Aug. 6, 2009 (54) METHOD OF INHIBITING (30) Foreign Application Priority Data POLYNEUROPATHIC PAIN WITH 3-(2-DIMETHYLAMINOMETHYLCYCLO- Feb. 4, 2008 (EP) ................................ O8 OO2 O13.4 HEXYL) PHENOL Publication Classification (75) Inventor: Thomas CHRISTOPH, Aachen (51) Int. Cl. (DE) A 6LX 3L/95 (2006.01) Correspondence Address: A63L/35 (2006.01) CROWELL & MORING LLP A6IP 29/00 (2006.01) INTELLECTUAL PROPERTY GROUP (52) U.S. Cl. ......................................... 514/567; 514/646 P.O. BOX 143OO WASHINGTON, DC 20044-4300 (US) (57) ABSTRACT (73) Assignee: Gruenenthal GmbH, Aachen (DE) A method of using 3-(2-dimethylaminomethylcyclohexyl) phenol or a pharmaceutically acceptable salt thereof as an (21) Appl. No.: 12/364,108 active pharmaceutical ingredient for treating or inhibiting polyneuropathic pain, in particular in diabetic polyneuropa (22) Filed: Feb. 2, 2009 thy. US 2009/O 197960 A1 Aug. 6, 2009 METHOD OF INHIBITING tingle and be unpleasantly numb, while more severe forms are POLYNEUROPATHIC PAIN WITH manifested as polyneuropathic pain, which is frequently per 3-(2-DIMETHYLAMINOMETHYLCYCL ceived as a burning pain. Erroneous sensations, such as for OHEXYL) PHENOL example a feeling of cold, heat or Swelling, may also occur. 0009. The signs and symptoms of polyneuropathy may be CROSS REFERENCE TO RELATED subdivided into three groups: (i) small-fibre sensory (for APPLICATIONS example burning pain, cutaneous hyperaesthesia, paraesthe 0001. This application claims priority from European sia, shooting pain, loss of pain and temperature perception, patent application no. EP08.002013.4, filed Feb.
    [Show full text]